Wedge Capital Management L L P NC boosted its stake in shares of Mednax, Inc (NYSE:MD) by 9.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,122,512 shares of the company’s stock after buying an additional 182,025 shares during the period. Mednax comprises approximately 1.2% of Wedge Capital Management L L P NC’s holdings, making the stock its 14th largest position. Wedge Capital Management L L P NC’s holdings in Mednax were worth $128,136,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in MD. PNC Financial Services Group Inc. raised its position in Mednax by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock valued at $632,000 after buying an additional 47 shares in the last quarter. Pacer Advisors Inc. raised its position in Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares in the last quarter. Morgan Dempsey Capital Management LLC raised its position in Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock valued at $157,000 after buying an additional 78 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Mednax by 3.0% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,122 shares of the company’s stock valued at $217,000 after buying an additional 92 shares in the last quarter. Finally, LS Investment Advisors LLC raised its position in Mednax by 1.6% in the first quarter. LS Investment Advisors LLC now owns 6,041 shares of the company’s stock valued at $419,000 after buying an additional 94 shares in the last quarter.

Mednax, Inc (MD) opened at 42.10 on Friday. Mednax, Inc has a 12 month low of $41.90 and a 12 month high of $72.13. The firm has a 50 day moving average price of $54.64 and a 200-day moving average price of $61.63. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of 13.41 and a beta of 0.40.

Mednax (NYSE:MD) last announced its earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm had revenue of $843 million during the quarter, compared to the consensus estimate of $849.49 million. During the same quarter in the prior year, the company earned $1.03 EPS. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. On average, equities analysts forecast that Mednax, Inc will post $3.31 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Mednax, Inc (NYSE:MD) Shares Bought by Wedge Capital Management L L P NC” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/11/mednax-inc-nysemd-shares-bought-by-wedge-capital-management-l-l-p-nc.html.

Several equities analysts recently commented on MD shares. Mizuho reduced their price target on Mednax from $64.00 to $58.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 30th. Jefferies Group LLC reissued a “hold” rating and set a $58.00 price target on shares of Mednax in a research report on Wednesday, April 26th. TheStreet lowered Mednax from a “b-” rating to a “c+” rating in a research report on Tuesday, May 16th. BidaskClub raised Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Stephens raised Mednax from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $55.00 to $68.00 in a research report on Thursday, June 22nd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $64.00.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the sale, the director now owns 18,072 shares in the company, valued at approximately $1,040,405.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joseph M. Calabro sold 23,327 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the completion of the sale, the insider now owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The disclosure for this sale can be found here. 2.40% of the stock is owned by corporate insiders.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.